Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep203 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Is there an association between sex steroids and biopsy-proven non-alcoholic fatty liver disease in obese men? A cross-sectional analysis of 134 men

Herdt Carlien De , Block Christophe De , Kristof Van Dessel , An Verrijken , Francque Sven , Dirinck Eveline

Background and aimsLow levels of testosterone and non-alcoholic fatty liver disease (NAFLD) in obese men are both linked to the metabolic syndrome, but the independent association between testosterone and NAFLD needs to be elucidated. In this cross-sectional analysis the association between total testosterone (total T) and calculated free testosterone (cFT) on the one hand and NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis on the other hand was...

ea0079011 | Abstracts | BES2021

A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in 134 obese men

Herdt C De , Block C De , A Verrijken , Dessel K Van , S Francque , L Van Gaal , E Dirinck

Background and aims: Low levels of testosterone and non-alcoholic fatty liver disease (NAFLD) in obese men are both linked to the metabolic syndrome, but the independent association between testosterone and NAFLD needs to be elucidated. In this cross-sectional analysis the association between total testosterone (total T) and calculated free testosterone (cFT) on the one hand and NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis on the other hand was investigated in obes...

ea0044oc1.4 | Early Career Oral Communications | SFEBES2016

The urinary steroid metabolome as a non-invasive tool to stage non-alcoholic fatty liver disease

Moolla Ahmad , Amin Amin , Hughes Bev , Arlt Wiebke , Hassan-Smith Zaki , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Biehl Michael , Tomlinson Jeremy

Introduction: Dysregulation of glucocorticoid (GC) metabolism is implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The only available treatment for NAFLD is weight loss and the gold standard diagnostic test is liver biopsy, which is invasive and resource intensive. NAFLD ranges from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and cirrhosis. It may be regarded as the hepatic manifestation of the metabolic syndrome and is strongl...

ea0041gp173 | Receptors & Signalling | ECE2016

The changing ‘steroid metabolome’ across the spectrum of non-alcoholic fatty liver disease

Moolla Ahmad , Amin Amin , Hughes Bev , Arlt Wiebke , Hassan-Smith Zaki , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Biehl Michael , Tomlinson Jeremy

Introduction: Dysregulated glucocorticoid (GC) metabolism has been implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). NAFLD extends from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and consequent cirrhosis. It is often regarded as the hepatic manifestation of the metabolic syndrome and is independently associated with increased liver and cardiovascular mortality. Changes in GC metabolism have thus far been described in small num...

ea0037gp.13.02 | Diabetes and obesity – Translational cardiovascular and obesity | ECE2015

Screening for genetic and structural variation in the NPY2R gene in obese children and adolescents

Aerts Evi , Zegers Doreen , Sorber Laure , Beckers Sigri , Verrijken An , Massa Guy , Hoorenbeeck Kim Van , Verhulst Stijn L , Gaal Luc F Van , Hul Wim Van

Objective: NPY2R is a G-protein-coupled receptor which is highly expressed in orexigenic NPY/AGRP neurons within the arcuate nucleus, a major integrator of appetite control in the hypothalamus. Genetic evidence coming from animal and association studies, has identified NPY2R as a candidate gene for obesity. Therefore we have designed an extensive mutation and CNV-analysis investigating the prevalence of genetic and structural variation in NPY2R.Design an...

ea0049oc3.5 | Receptors & Signalling | ECE2017

Accurate staging of non-alcoholic fatty liver disease through analysis of the urinary steroid metabolome

Moolla Ahmad , Amin Amin , Hughes Beverly , Arlt Wiebke , Hassan-Smith Zaki , Gilligan Lorna , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Grove Jane , Guha Neil , Aithal Guruprasad , Barnes Ellie , Biehl Michael , Tomlinson Jeremy

Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with dysregulated glucocorticoid metabolism. Advanced stages of NAFLD are associated with adverse outcome and current strategies to stage disease severity are still reliant upon liver biopsy. We have previously described changes to enzymatic pathways that regulate cortisol bioavailability; 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1) regenerates cortisol from inactive cortisone, and A-ring re...

ea0059oc3.3 | Obesity & diabetes | SFEBES2018

Staging of non-alcoholic fatty liver disease through LC-MS/MS analysis of the urinary steroid metabolome

Moolla Ahmad , Taylor Angela , Gilligan Lorna , Boer Jasper De , Amin Amin , Pavlov David , Hughes Beverly , Hassan-Smith Zaki , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Grove Jane , Guha Neil , Aithal Guruprasad , Barnes Ellie , Arlt Wiebke , Biehl Michael , Tomlinson Jeremy

Introduction: The development of accurate non-invasive markers to diagnose and stage non-alcoholic fatty liver disease (NAFLD) is of high importance to reduce the need for an invasive liver biopsy. These markers help to stratify patients at highest risk of hepatic and cardio-metabolic complications and allow tracking of disease progression and treatment response. We have previously described alterations in glucocorticoid metabolism that are differentially regulated across the ...